Streetbeat News

Analyst Ratings

TDG

Deutsche Bank analyst Scott Deuschle maintains a Buy rating on TransDigm Group (NYSE:TDG) and raises the price target from $1524 to $1577.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:40 am

HXL

Deutsche Bank analyst Scott Deuschle maintains a Hold rating on Hexcel (NYSE:HXL) but lowers the price target from $65 to $62.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:39 am

URGN

HC Wainwright & Co. has reiterated its Buy rating for UroGen Pharma, maintaining a price target of $60. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:38 am

BA

Deutsche Bank analyst Scott Deuschle maintains a Buy rating on Boeing but lowers the price target from $225 to $195.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:37 am

GE

Deutsche Bank analyst Scott Deuschle maintains a Buy rating on GE Aero and raises the price target from $212 to $235.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:35 am

KHC

PM

WBA

The article highlights three high-dividend yielding stocks in the consumer staples sector: Walgreens Boots Alliance, Kraft Heinz, and Philip Morris International. Analysts have provided ratings and price targets for these stocks, with recent news impacting their outlook.

Portfolio Pulse from Avi Kapoor

October 03, 2024 | 11:33 am

BWXT

Deutsche Bank analyst Scott Deuschle has maintained a Buy rating on BWX Technologies and raised the price target from $113 to $129.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:33 am

HWM

Deutsche Bank analyst Scott Deuschle maintains a Buy rating on Howmet Aerospace and raises the price target from $106 to $125.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:31 am

ATI

Deutsche Bank analyst Scott Deuschle maintains a Buy rating on ATI and raises the price target from $81 to $84.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:29 am

ABOS

HC Wainwright & Co. has reiterated its Buy rating on Acumen Pharmaceuticals, maintaining a price target of $15. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:28 am